Tourmaline Bio (NASDAQ:TRML) Rating Reiterated by Leerink Partnrs
Leerink Partnrs reaffirmed their outperform rating on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a report issued on Thursday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.00) EPS. TRML has been the subject of a number of other reports. Piper Sandler started coverage on Tourmaline Bio […]
More Stories
Trump Admin Aims to Create Family-Friendly Airports With Healthier Foods, Exercise Areas
By Jill McLaughlin The Trump administration is ready to spend $1 billion to create healthier food options, private breastfeeding pods,...
Trump Tells Xi US Will Ship Nvidia H200 Chips to ‘Approved Customers’ in China
By Catherine Yang President Donald Trump announced on Truth Social on Dec. 8 that he told Chinese Communist Party (CCP)...
Trump Announces $12 Billion Farm Aid Program
By Jacob Burg President Donald Trump on Dec. 8 unveiled a $12 billion economic assistance package for farmers. The Trump...
Paramount Launches $108.4 Billion Hostile Bid to Buy Warner Bros.
By Andrew Moran In a last-ditch effort to acquire the Warner Bros. entertainment empire, Paramount Skydance has launched a hostile...
Air Transat Pilots Issue Strike Notice, Causing Flight Suspensions
By Olivia Gomm The union representing Air Transat pilots has issued a 72-hour strike notice, saying that the pilots intend...
Dollar General Plans to Open 450 New Stores in US in 2026
By Rob Sabo Backed by strong third-quarter net sales of $10.6 billion, Dollar General on Dec. 4 said it plans...